During Monday’s Current trade, Shares of Dana Holding Corporation (NYSE:DAN), lost -2.06% to $20.90.
Dana Holding Corporation (DAN) officially inaugurated its 16th global technology center in Cedar Park, Texas. Presently employing 35 engineers and support staff with capacity for more than 80, the 40,000 square-foot facility is devoted to the engineering and production of the company’s VariGlide® technology, a revolutionary new transmission design that incorporates continuously variable planetary (CVP) technology for use in light-vehicle and many off-highway transmissions.
Developed through a planned licensing relationship between Dana and Fallbrook Technologies Inc., VariGlide technology enables designers to reduce the complexity of transmissions while enabling the engine to operate at more efficient speeds – ultimately increasing fuel efficiency, reducing emissions, and improving overall vehicle performance.
Dana Holding Corporation manufactures and sells driveline, sealing, and thermal-administration products for vehicle manufacturers in North America, Europe, South America, and the Asia Pacific. The company operates in four segments: Light Vehicle Driveline Technologies, Commercial Vehicle Driveline Technologies, Off-Highway Driveline Technologies, and Power Technologies. The Light Vehicle Driveline Technologies segment offers front axles, rear axles, driveshafts, differentials, torque couplings, and modular assemblies for use in light trucks, sport utility vehicles, crossover utility vehicles, vans, and passenger cars.
Shares of General Growth Properties Inc (NYSE:GGP), declined -0.08% to $26.27, during its current trading session.
General Growth Properties, Inc. (GGP) will report financial and operational results for the second quarter 2015 after the close of business on Monday, August 3, 2015, and host a conference call for investors and other interested parties at 8:00 a.m. Central (9:00 a.m. Eastern) on Tuesday, August 4, 2015. The information to be talk abouted during the call will be contained in the earnings release and supplemental financial package which will be accessible on the Investors section of the company’s website at www.ggp.com.
General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.
ITC Holdings Corp. (NYSE:ITC), during its Monday’s current trading session gained 0.59% to $32.59.
ITC Lake Erie Connector LLC, a wholly-owned partner of ITC Holdings Corp., (ITC) the largest independent electricity transmission company in the United States, recently commenced an open solicitation for interest in transmission capacity on the ITC Lake Erie Connector line. Startning recently and through August 21, ITC intends to solicit expressions of interest from qualified parties for firm transmission rights at negotiated rates.
The ITC Lake Erie Connector is a projected 1000 MW, bi-directional, High-Voltage Direct Current (HVDC) merchant transmission line that will provide the first direct link between the markets of the Ontario Independent Electricity System Operator (IESO) and PJM Interconnection, LLC (PJM). The ITC Lake Erie Connector will enable transmission customers to more efficiently access energy, capacity and renewable energy credit opportunities in both markets.
ITC Holdings Corp., together with its auxiliaries, engages in the transmission of electricity in the United States. The company functions as conduit, allowing for power from generators to be transmitted to local distribution systems through its own systems or in conjunction with neighboring transmission systems. It owns and operates high-voltage transmission facilities in Michigan’s Lower Peninsula and portions of Iowa, Minnesota, Illinois, Missouri, Kansas, and Oklahoma. The company serves investor-owned utilities, municipalities, cooperatives, power marketers, and alternative energy suppliers.
Finally, Concert Pharmaceuticals, Inc. (NADAQ:CNCE), decreased -4.25%, to $14.70.
Concert Pharmaceuticals, Inc. (CNCE) declared that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is following a September 2011 patent assignment agreement between Concert and Auspex whereby Concert assigned to Auspex a U.S. patent application regarding deuterium-substituted analogs of pirfenidone. Under the agreement, Concert became eligible to receive the payment due to a change of control of Auspex, which was attained by Teva Pharmaceuticals Industries Ltd on May 5, 2015.
Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer. The company’s clinical-stage product candidates comprise AVP-786, which is in Phase II clinical trial for the treatment of neurologic and psychiatric disorders, counting pain, behavioral disorders, mood disorders, and movement disorders; CTP-499 that is in Phase II clinical trial for chronic kidney disease in patients with type 2 diabetes; and CTP-354, which is in Phase I clinical trial to spasticity associated with spinal cord injury and multiple sclerosis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
